Management of patients with HBeAg-negative chronic hepatitis B
- PMID: 17267676
- PMCID: PMC2599959
- DOI: 10.1136/pgmj.2006.044826
Management of patients with HBeAg-negative chronic hepatitis B
Abstract
Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.
Conflict of interest statement
Competing interests: None declared.
References
-
- Mast E E, Alter M J, Margolis H S. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999171730–1733. - PubMed